{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=7&sponsor=Boehringer+Ingelheim",
    "query": {
      "sponsor": "Boehringer Ingelheim",
      "page": 7
    },
    "page_size": 10
  },
  "pagination": {
    "page": 7,
    "page_size": 10,
    "total_count": 673,
    "total_pages": 68,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=8&sponsor=Boehringer+Ingelheim&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=6&sponsor=Boehringer+Ingelheim&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-11T01:45:32.394Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02802345",
      "title": "Efficacy and Safety of Nintedanib Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Idiopathic Pulmonary Fibrosis"
      ],
      "interventions": [
        {
          "name": "Nintedanib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Sildenafil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 274,
      "start_date": "2016-06-30",
      "completion_date": "2018-04-13",
      "has_results": true,
      "last_update_posted_date": "2019-01-11",
      "last_synced_at": "2026-10-11T01:45:32.394Z",
      "location_count": 17,
      "location_summary": "Birmingham, Alabama • Stamford, Connecticut • Jacksonville, Florida + 13 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Stamford",
          "state": "Connecticut"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02802345"
    },
    {
      "nct_id": "NCT05865886",
      "title": "A Study to Test How Well BI 1291583 is Tolerated by People With Cystic Fibrosis Bronchiectasis (Clairafly™)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cystic Fibrosis",
        "Bronchiectasis"
      ],
      "interventions": [
        {
          "name": "BI 1291583",
          "type": "DRUG"
        },
        {
          "name": "Placebo to BI 1291583",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2024-04-05",
      "completion_date": "2024-10-07",
      "has_results": true,
      "last_update_posted_date": "2026-06-23",
      "last_synced_at": "2026-10-11T01:45:32.394Z",
      "location_count": 7,
      "location_summary": "Denver, Colorado • Altamonte Springs, Florida • South Portland, Maine + 3 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Altamonte Springs",
          "state": "Florida"
        },
        {
          "city": "South Portland",
          "state": "Maine"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05865886"
    },
    {
      "nct_id": "NCT04399837",
      "title": "A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Generalized Pustular Psoriasis"
      ],
      "interventions": [
        {
          "name": "Spesolimab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "12 Years to 75 Years"
      },
      "enrollment_count": 123,
      "start_date": "2020-06-04",
      "completion_date": "2022-11-23",
      "has_results": true,
      "last_update_posted_date": "2025-10-20",
      "last_synced_at": "2026-10-11T01:45:32.394Z",
      "location_count": 2,
      "location_summary": "Auburn Hills, Michigan • St Louis, Missouri",
      "locations": [
        {
          "city": "Auburn Hills",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04399837"
    },
    {
      "nct_id": "NCT01634113",
      "title": "Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo in 1 to 5 Year Old Patients With Persistent Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "tiotropium-bromide",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "5 Years",
        "sex": "ALL",
        "summary": "1 Year to 5 Years"
      },
      "enrollment_count": 102,
      "start_date": "2012-07",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2015-06-23",
      "last_synced_at": "2026-10-11T01:45:32.394Z",
      "location_count": 4,
      "location_summary": "Columbia, Missouri • Oklahoma City, Oklahoma • Charleston, South Carolina + 1 more",
      "locations": [
        {
          "city": "Columbia",
          "state": "Missouri"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        },
        {
          "city": "Summerville",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01634113"
    },
    {
      "nct_id": "NCT06082843",
      "title": "A Study to Test Whether Avenciguat Helps People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) Who Had Bleeding in the Esophagus or Fluid Accumulation in the Belly",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hypertension, Portal",
        "Liver Cirrhosis"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Avenciguat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 22,
      "start_date": "2024-01-03",
      "completion_date": "2024-05-30",
      "has_results": true,
      "last_update_posted_date": "2025-06-12",
      "last_synced_at": "2026-10-11T01:45:32.394Z",
      "location_count": 2,
      "location_summary": "Pasadena, California • Rialto, California",
      "locations": [
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Rialto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06082843"
    },
    {
      "nct_id": "NCT02695290",
      "title": "Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung",
        "ErbB Receptors"
      ],
      "interventions": [
        {
          "name": "Afatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2016-03-17",
      "completion_date": "2016-08-26",
      "has_results": true,
      "last_update_posted_date": "2017-09-18",
      "last_synced_at": "2026-10-11T01:45:32.394Z",
      "location_count": 1,
      "location_summary": "Fountain Valley, California",
      "locations": [
        {
          "city": "Fountain Valley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02695290"
    },
    {
      "nct_id": "NCT00190632",
      "title": "To Evaluate the Safety in Patients Taking Duloxetine for Stress Urinary Incontinence",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Stress Urinary Incontinence"
      ],
      "interventions": [
        {
          "name": "Duloxetine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 600,
      "start_date": "2001-03",
      "completion_date": "2006-04",
      "has_results": false,
      "last_update_posted_date": "2007-01-26",
      "last_synced_at": "2026-10-11T01:45:32.394Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00190632"
    },
    {
      "nct_id": "NCT03156114",
      "title": "This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms",
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "Ezabenlimab",
          "type": "DRUG"
        },
        {
          "name": "BI 754111",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 172,
      "start_date": "2017-06-13",
      "completion_date": "2023-06-06",
      "has_results": true,
      "last_update_posted_date": "2026-01-26",
      "last_synced_at": "2026-10-11T01:45:32.394Z",
      "location_count": 6,
      "location_summary": "Miami, Florida • Sarasota, Florida • Hackensack, New Jersey + 3 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03156114"
    },
    {
      "nct_id": "NCT00291330",
      "title": "Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Thromboembolism"
      ],
      "interventions": [
        {
          "name": "dabigatran etexilate 150 mg",
          "type": "DRUG"
        },
        {
          "name": "warfarin (INR 2-3)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2564,
      "start_date": "2006-02",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2014-06-06",
      "last_synced_at": "2026-10-11T01:45:32.394Z",
      "location_count": 23,
      "location_summary": "Mobile, Alabama • Hartford, Connecticut • Clearwater, Florida + 19 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00291330"
    },
    {
      "nct_id": "NCT01090011",
      "title": "Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "Cetuximab",
          "type": "DRUG"
        },
        {
          "name": "BIBW 2992",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 171,
      "start_date": "2010-03",
      "completion_date": "2014-08",
      "has_results": true,
      "last_update_posted_date": "2015-10-02",
      "last_synced_at": "2026-10-11T01:45:32.394Z",
      "location_count": 4,
      "location_summary": "Aurora, Colorado • New Haven, Connecticut • New York, New York + 1 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01090011"
    }
  ]
}